A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease.
Phase of Trial: Phase III
Latest Information Update: 15 Dec 2015
At a glance
- Drugs Taliglucerase alfa (Primary)
- Indications Gaucher's disease
- Focus Therapeutic Use
- Sponsors Protalix Biotherapeutics
- 11 Dec 2015 Protocol has been amended from change in time frame of primary endpoint from 21 months to 60 months,
- 10 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jun 2014 New trial record